Assessment of economic efficiency of the diagnostic medical device "LifeRing" for early diagnosis of influenza in the clinical practice of the subjects of the Russian Federation at the level of inpatient care. Our working hypothesis was: compared with PCR, when using the LIFRING medical device, flu therapy begins within the first 48 hours after the onset of disease symptoms, which reduces the relative risk of complications - heart failure by 48%, acute otitis media by 19%, asthma by 13% and pneumonia by 10%. In this work, only direct medical costs were taken into account: - The cost of medical care at the level of inpatient care - Costs of PCR diagnostics - Costs of implementing a new diagnostic method using the LifeRing medical device - Costs for treating complications The costs of treating recognized and unrecognized influenza in the Russian Federation are 63,893,983,049 rubles, in Moscow - 11,789,228,778 rubles, in the Moscow Region - 3,541,582,643 rubles, in the Republic of Tatarstan - 1,276,832,837 rubles. and in St. Petersburg - 3 364 679 639 rubles. Under the conditions of simulated practice, if LifeRing medical device is introduced for the diagnosis of influenza in the Russian Federation, the total economic burden will be reduced by 2.21 billion rubles. In the case of the introduction of the LifeRing medical device for the diagnosis of influenza in the city of Moscow, the total economic burden will be reduced by 0.09 billion rubles, in the Moscow region by 0.12 billion rubles, in the Republic of Tatarstan by 0.04 billion rubles and in St. Petersburg by 0.15 billion rubles. Implementation of the LifeRing medical device for the diagnosis of influenza in the clinical practice of the Russian Federation is economically feasible.
Read full abstract